Current Practices in Genetic Testing for Prostate Cancer: The Indian Scenario.
Journal
Indian journal of public health
ISSN: 0019-557X
Titre abrégé: Indian J Public Health
Pays: India
ID NLM: 0400673
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
12
05
2023
accepted:
27
12
2023
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
ppublish
Résumé
Despite genetic testing being recommended by international guidelines for the selection of targeted therapy for prostate cancer (PCa), limited data are available on genetic testing for PCa in India. The objective is to understand the current genetic testing practice pattern for PCa in India. A panel of 9 experts developed and validated a premeeting online questionnaire comprising 12 objective questions. The questionnaire was circulated from February 2022 to May 2022 among medical oncologists and uro-oncologists across pan-India, followed by response collection over 3 months. Descriptive statistics were used to summarize results and concluding statements were formulated on current genetic testing practice patterns for PCa. A total of 103 responses were received. Genetic testing was advised by 35.9% of the participants in <5% of patients with PCa. Patients with a family history of PCa (88.3%) were most commonly referred for genetic testing. Nearly half (50.2%) of the participants routinely tested for homologous recombination repair (HRR) genes; 52% used blood and tissue as the most preferred specimen for performing genetic testing and 44.7% followed the testing sequence of tumor tissue followed by blood. Major barriers to genetic testing were affordability and scarcity of genetic counselors, while a major change could be brought by making it cost-effective and improving access to medication. We observed a lower prescription frequency of genetic testing for the HRR gene across pan-India. Improving the quality and access to genetic testing and the availability of cost-effective-targeted therapies will aid in delivering personalized care to patients with metastatic PCa.
Sections du résumé
BACKGROUND
BACKGROUND
Despite genetic testing being recommended by international guidelines for the selection of targeted therapy for prostate cancer (PCa), limited data are available on genetic testing for PCa in India.
OBJECTIVES
OBJECTIVE
The objective is to understand the current genetic testing practice pattern for PCa in India.
MATERIALS AND METHODS
METHODS
A panel of 9 experts developed and validated a premeeting online questionnaire comprising 12 objective questions. The questionnaire was circulated from February 2022 to May 2022 among medical oncologists and uro-oncologists across pan-India, followed by response collection over 3 months. Descriptive statistics were used to summarize results and concluding statements were formulated on current genetic testing practice patterns for PCa.
RESULTS
RESULTS
A total of 103 responses were received. Genetic testing was advised by 35.9% of the participants in <5% of patients with PCa. Patients with a family history of PCa (88.3%) were most commonly referred for genetic testing. Nearly half (50.2%) of the participants routinely tested for homologous recombination repair (HRR) genes; 52% used blood and tissue as the most preferred specimen for performing genetic testing and 44.7% followed the testing sequence of tumor tissue followed by blood. Major barriers to genetic testing were affordability and scarcity of genetic counselors, while a major change could be brought by making it cost-effective and improving access to medication.
CONCLUSIONS
CONCLUSIONS
We observed a lower prescription frequency of genetic testing for the HRR gene across pan-India. Improving the quality and access to genetic testing and the availability of cost-effective-targeted therapies will aid in delivering personalized care to patients with metastatic PCa.
Identifiants
pubmed: 39321228
doi: 10.4103/ijph.ijph_686_23
pii: 01586002-202407000-00010
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-400Informations de copyright
Copyright © 2024 Copyright: © 2024 Indian Journal of Public Health.
Références
Jang A, Sartor O, Barata PC, Paller CJ. Therapeutic potential of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer. Cancers (Basel) 2020;12:3467.
Clark R, Herrera-Caceres J, Kenk M, Fleshner N. Clinical management of prostate cancer in high-risk genetic mutation carriers. Cancers (Basel) 2022;14:1004.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–28.
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375:443–53.
Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Guideline Prostate Cancer. V.1.2023. ©National Comprehensive Cancer Network, Inc. 2022. _All Rights Reserved. To View the Most Recent and Complete Version of_The Guideline, Go Online to NCCN.org. NCCN Makes no Warranties of any Kind Whatsoever Regarding their Content, use or Application and Disclaims any Responsibility for their Application or use in any Way Available from: https://www. NCCN.org [Last accessed on 2022 Oct 13].
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1119–34.
Kanesvaran R, Castro E, Wong A, Fizazi K, Chua ML, Zhu Y, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open 2022;7:100518.
European Society for Medical Oncology. OncologyPRO:Guidelines for Genetic Testing Available from: https://oncologypro.esmo.org/oncology-in-practice/anti-cancer-agents-and-biological-therapy/parp-inhibition-and-dna-damage-response-ddr/parp-inhibitors/clinical-activity/prostate-cancer/diagnostics-and-patient-selection-in-prostate-cancer/guidelines-for-genetic-testing [Last accessed on 2022 Dec 22, Last updated on 2021 May 04].
Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B:A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2019;37:490–503.
Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38:3763–72.
Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol 2021;17:2907–21.
Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, et al. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. Future Oncol 2022;18:937–51.
Thakker S, Loeb S, Giri V, Matulewicz R. PD13-03 lack of awareness and underutilization of genetic testing in prostate cancer. J Urol 2022;207:e251.
Bazarbashi S, Su WP, Wong SW, Singarachari RA, Rawal S, Volkova MI, et al. ANarrative review of implementing precision oncology in metastatic castration-resistant prostate cancer in emerging countries. Oncol Ther 2021;9:311–27.
Mandal RK, Gangwar R, Kapoor R, Mittal RD. Polymorphisms in base-excision and nucleotide-excision repair genes and prostate cancer risk in north Indian population. Indian J Med Res 2012;135:64–71.
Gupta A, Shukla N, Nehra M, Gupta S, Malik B, Mishra AK, et al. Apilot study on the whole exome sequencing of prostate cancer in the Indian phenotype reveals distinct polymorphisms. Front Genet 2020;11:874.
Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, et al. Germline genetic testing in advanced prostate cancer;practices and barriers:Survey results from the germline genetics working group of the prostate cancer clinical trials consortium. Clin Genitourin Cancer 2019;17:275–82.e1.
Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional adoption of commercial gene expression testing for prostate cancer. JAMA Oncol 2021;7:52–8.
Aguiar JA, Li EV, Siddiqui MR, Soliman MA, Kumar SK, Schaeffer EM, et al. Utilization of genetic testing in men with advanced prostate cancer. Prostate 2023;83:516–23.
Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin ME. Genetic testing in prostate cancer management:Considerations informing primary care. CA Cancer J Clin 2022;72:360–71.
Berchuck JE, Zhang Z, Silver R, Kwak L, Xie W, Lee GM, et al. Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer. Eur Urol 2021;80:295–303.
Nair-Shalliker V, Bang A, Egger S, Yu XQ, Chiam K, Steinberg J, et al. Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study. Br J Cancer 2022;127:735–46.
Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, et al. Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA. JAMA Oncol 2021;7:1–5.
Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, et al. Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer. J Clin Oncol 2017;35:189.
Chiu PK, Lee EK, Chan MT, Chan WH, Cheung MH, Lam MH, et al. Genetic testing and its clinical application in prostate cancer management:Consensus statements from the Hong Kong urological association and Hong Kong Society of uro-oncology. Front Oncol 2022;12:962958.
de Bono JS, Fizazi K, Saad F, Shore N, Sandhu SK, Mehra N, et al. 847PD –Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Ann Oncol 2019;30:v328–9.
Sokolova A, Cheng H. Germline testing in prostate cancer:When and who to test. Oncology (Williston Park) 2021;35:645–53.
Russo J, Giri VN. Germline testing and genetic counselling in prostate cancer. Nat Rev Urol 2022;19:331–43.
Tong B, Borno H, Small EJ, Alagala F, Blanco A, Dhawan MS. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. J Clin Oncol 2020;38:1590.
Qu M, Zhao X, Chen H, Bai Y. 1964P Genomic characteristics of homologous recombination in prostate cancer patients. Ann Oncol 2020;31:S1105.